{Reference Type}: Journal Article
{Title}: How should anti-hypertensive medications be adjusted before screening for primary aldosteronism?
{Author}: Lu JY;Chang YY;Lee TW;Wu MH;Chen ZW;Huang YT;Lai TS;Er LK;Lin YH;Wu VC;Cheng HM;Kao HL;Jia-Yin Hou C;Wu KD;Chen ST;Liu FH;
{Journal}: J Formos Med Assoc
{Volume}: 123
{Issue}: 0
{Year}: 2024 Mar 6
{Factor}: 3.871
{DOI}: 10.1016/j.jfma.2023.05.021
{Abstract}: Anti-hypertensive medications may affect plasma renin activity and/or plasma aldosterone concentration, misleading the interpretation of the aldosterone-to-renin ratio when screening for primary aldosteronism. The Task Force of Taiwan PA recommends that, when necessary, using α-adrenergic receptor blocking agents, centrally acting α-adrenergic agonists, and/or non-dihydropyridine calcium channel blockers should be considered to control blood pressure before screening for PA. We recommend temporarily holding β-adrenergic receptor blocking agents, mineralocorticoid receptor antagonists, dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and all diuretics before screening for PA. Further large-scale randomized controlled studies are required to confirm the recommendations.